PIK3CA and acute lymphoblastic leukemia: In contrast to other PI3K pathway inhibitors studied by the PPTP/C, rapamycin induced objective responses, with a 14 % ORR among 37 solid tumor models studied and a 38 % ORR among 8 ALL models studied (Table 7).